BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Guberna L, Nyssen OP, Chaparro M, Gisbert JP. Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis. J Clin Med 2021;10:2132. [PMID: 34069295 DOI: 10.3390/jcm10102132] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Levartovsky A, Kopylov U. Comprehensive Management of Inflammatory Bowel Disease: What's Next. J Clin Med 2022;11:4584. [PMID: 35956200 DOI: 10.3390/jcm11154584] [Reference Citation Analysis]
2 Srinivasan A, Gilmore R, van Langenberg D, De Cruz P. Systematic review and meta-analysis: evaluating response to empiric anti-TNF dose intensification for secondary loss of response in Crohn’s disease. Therap Adv Gastroenterol 2022;15:175628482110709. [DOI: 10.1177/17562848211070940] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Gisbert JP, Chaparro M. Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)? J Clin Med 2021;10:5318. [PMID: 34830595 DOI: 10.3390/jcm10225318] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
4 Herrlinger K, Stange EF. Therapie-Update Morbus Crohn 2021. Gastro-News 2021;8:26-33. [DOI: 10.1007/s15036-021-2391-0] [Reference Citation Analysis]